41
Participants
Start Date
May 11, 2017
Primary Completion Date
February 21, 2019
Study Completion Date
February 21, 2019
Proleukin
Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10\^6 - 3.0 X 10\^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10\^6 IU will be allowed per day.
Placebo Injection
Dextrose 5%
Addenbrooke's Hospital, Cambridge
University of Cambridge
OTHER
Cambridge University Hospitals NHS Foundation Trust
OTHER